News

Cautious Optimism As Merck Leans On Oncology Amid Gardasil Vaccine Concerns
Merck Q2 earnings beat estimates but revenue fell short. Gardasil sales dropped while Keytruda and other treatments drove ...
Merck CEO Sees Minimal EU Tariffs Impact, Warns Of Gardasil Challenges
Merck & Co. Inc. (NYSE:MRK) shares fell over 6% in early trading Tuesday after the pharmaceutical giant reported a mixed ...
Merck extends pause on China Gardasil shipments to year end, shares slip
Merck said on Tuesday it was extending its pause on Gardasil shipments to China until at least the end of 2025 due to ...
Merck to extend pause on China Gardasil shipments to year end
Merck & Co said on Tuesday it was extending its hold on Gardasil shipments to China until at least the end of 2025 due to ...
Merck to cut jobs and costs as demand for Gardasil in China remains weak
Merck & Co on Tuesday announced job and cost cuts that it said will save $3 billion a year, after it posted lower ...
Merck hit by sharp decline in HPV vaccine sales in China
The Gardasil human papillomavirus virus vaccine remains Merck’s second best-selling drug behind cancer treatment Keytruda.
Investor's Business Daily on MSN3d
Merck Stock Falls After Layoff Announcement, Gardasil Sales Drop
Merck stock fell early Tuesday after Q2 results. The Dow Jones drugmaker plans for job cuts as part of restructuring ...
FiercePharma23d
China's 9-valent HPV vaccine priced at 60% discount on Merck shot
China’s first domestically made nine-valent HPV vaccine, a direct competitor to Merck’s Gardasil 9, is being priced at 499 yuan ($70) per dose, the state-owned Xinhua News Agency reports.